New stock news | True Health Medical sprints for Hong Kong IPO: approved by China Securities Regulatory Commission filing

On May 29, the International Cooperation Department of the China Securities Regulatory Commission issued a "Filing Notice on the Overseas Issuance and Listing as well as the 'Full Circulation' of Unlisted Shares in Mainland China of Guangdong Zhenjiankang Medical Technology Development Co., Ltd.", confirming the filing of the overseas issuance and listing as well as the "full circulation" of shares of Guangdong Zhenjiankang Medical Technology Development Co., Ltd. (referred to as "Zhenjiankang Medical"). According to the filing notice, Zhenjiankang Medical plans to issue up to 9.2236 million shares of overseas listed common stock, and list on the Hong Kong Stock Exchange. At the same time, 35 shareholders of the company intend to convert a total of 32.082303 million shares of unlisted shares in mainland China into overseas listed shares, and list for circulation on the Hong Kong Stock Exchange. Public information shows that Zhenjiankang Medical was established in 2018 and is a provider of precise minimally invasive diagnosis and treatment solutions with artificial intelligence and Siasun Robot & Automation technology as its core, mainly focusing on precise puncture diagnosis and treatment for lung and abdominal tumors in various clinical scenarios. The company has formed a product matrix of Siasun Robot & Automation surgery with precise puncture positioning and precise ablation treatment as its core, and has extended its reach to the field of warm preservation and intelligent evaluation of ex vivo organs. By 2025, Zhenjiankang Medical is positioned as the market leader in the puncture and ablation surgery Siasun Robot & Automation field in China. A search on the website of the National Medical Products Administration shows that Zhenjiankang Medical has obtained 9 Class III medical device registration certificates and 5 Class II medical device registration certificates so far. Among them, the "Puncture Surgery Navigation Positioning System" and the "Navigation Positioning Microwave Ablation System" have been recognized by the National Medical Products Administration as "domestically innovative" and "internationally innovative" respectively. The related products have been introduced into nearly 100 medical institutions nationwide, with more than 7,000 surgeries completed, and the technical feasibility and clinical value have been fully verified.